Assisted Chondrial Therapeutics, Inc., in entering into a definitive merger agreement with Zafgen, Inc., under which Chondrial will acquire Zafgen in a reverse merger wherein the stockholders of Chondrial will become the majority owners of Zafgen’s outstanding common stock. Stockholders of Chondrial will receive shares of newly issued Zafgen common stock equal to approximately 60% of the company following the merger.
McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.